Quick filters

50 trials match your criteria

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Dermatomyositis

Not recruiting

Study on Baricitinib for Treating New-Onset Juvenile Dermatomyositis in Children

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years

Study on Eteplirsen for Patients with Duchenne Muscular Dystrophy with Deletion Mutations Amenable to Exon 51 Skipping

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years

Study on the Long-Term Safety and Effectiveness of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Study on the Safety and Effects of mRNA-3745 for Patients with Glycogen Storage Disease Type 1a (GSD1a)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years

Study on the Effects of Fordadistrogene Movaparvovec for Patients with Duchenne Muscular Dystrophy

Registered drug
Countries:FranceFrance
  • Participants:0–17 years

Study on Long-term Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Adults with Late-onset Pompe Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Study on the Effectiveness and Safety of Satralizumab for Patients with Type 1 Facioscapulohumeral Muscular Dystrophy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Study on the Safety and Effectiveness of ABC008 for Patients with Inclusion Body Myositis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Muscular dystrophy

Not recruiting

Gene Therapy Study for Patients with Limb-Girdle Muscular Dystrophy Using GNT0006

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years

Study on the Long-term Effects of EDG-5506 for Adults and Adolescents with Becker Muscular Dystrophy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

powered byClinicalTrials.eu